Biolevate funding news – Paris-based Biolevate has Secured €6 Million in Seed Funding

Joël Belafa, Co-founder and CEO of Biolevate, highlighted the company’s mission: “Artificial intelligence has immense potential, and we established Biolevate with a clear mission of using AI to accelerate the development of new therapies, ensuring patients receive life-saving treatments faster. With our platform, medical writing can be accomplished at a much faster rate while ensuring accuracy of information at every stage of drug discovery and development – ultimately elevating the standard of healthcare.”

It’s platform, ELISE, uses advanced AI technologies like Natural Language Processing (NLP), Computer Vision, and Graph Neural Networks (GNN) to help medical writers create and manage detailed scientific documents.

The platform allows for real-time collaboration automated checks for regulatory compliance, and tools for data analysis all of which help speed up the process of bringing new medical products to market.

Read also - Taito.ai funding news - Helsinki-based Taito.ai has Secured €2.5 Million in Seed Funding

It points out that while pharmaceutical R&D spending has doubled in the last ten years, the process of creating regulatory documents is still slow and manual, worsened by a shortage of skilled medical writers.

Biolevate offering

It’s platform helps solve these problems by simplifying documentation processes ensuring it meets strict standards, and allowing researchers to focus on innovation instead of administrative work.

Julien Hobeika, Partner at EQT Ventures, commented: “There’s a significant opportunity in making medical writing more efficient using AI, and the team at Biolevate offers an impressive solution to transform medical documentation processes into a seamless and effective procedure that supports innovation and drives scientific breakthroughs benefiting society. At EQT Ventures, we support generation-defining companies that can convert their vision into global successes – and Joël and the team are just getting started: In the long run, their platform can augment any scientist, working with any type of materials.”

Purpose of fundraising

Biolevate plans to use the funding to improve its platform and grow its team. By tackling regulatory and operational challenges in therapy development, the company aims to speed up the availability of new treatments, make healthcare more accessible, and support global scientific progress.

About Biolevate

At Biolevate, they combine AI technology with human expertise to drive healthcare innovations, helping companies advance medical breakthroughs safely and ethically.